• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Savara Inc.

    6/8/26 4:15:38 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email
    8-K
    Savara Inc false 0001160308 --12-31 0001160308 2026-06-04 2026-06-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported)

    June 4, 2026

     

     

    SAVARA INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-32157   84-1318182

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1717 Langhorne Newtown Road, Suite 300
    Langhorne, PA 19047
    (Address of principal executive offices, including zip code)

    (512) 614-1848

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share   SVRA   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Amendment of 2024 Omnibus Incentive Plan

    On June 4, 2026, the stockholders of Savara Inc. (“Savara”) approved an amendment to the Savara Inc. 2024 Omnibus Incentive Plan (the “2024 Plan”), to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000 shares (the “2024 Plan Amendment”). The 2024 Plan Amendment was previously approved by Savara’s Board of Directors (the “Board”), subject to stockholder approval.

    The 2024 Plan Amendment is described in detail under “Proposal 3—Approval of an Amendment to our 2024 Omnibus Incentive Plan” of the Savara Definitive Proxy Statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”). The foregoing description of the 2024 Plan Amendment is qualified in its entirety by reference to the full text of the 2024 Plan, as amended by the 2024 Plan Amendment, which is attached to the Proxy Statement as Appendix B.

    Executive Transition

    On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the “Effective Date”). Mr. Lutz’s appointment follows the decision of David Lowrance to resign from his role as Savara’s Chief Financial and Administrative Officer, effective as of the Effective Date, due to health reasons. Mr. Lowrance will receive severance in accordance with the terms of Section 6(a) of his employment agreement and 12 months’ acceleration of the vesting of his unvested equity awards as of the Effective Date, provided that he signs and does not revoke a customary release in favor of Savara. The Company expects to enter into a consulting agreement with Mr. Lowrance pursuant to which he will provide advisory services at the rate of $200 per hour, and such agreement may be terminated by either party upon 30 days’ prior written notice. The foregoing description of the consulting agreement is qualified in its entirety by reference to the full text of the agreement, which will be filed as an exhibit to Savara’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

    Mr. Lutz, age 57, has served as Savara’s Chief Operating Officer since February 2023. Additional biographical information concerning Mr. Lutz can be found in the Proxy Statement under “Executive Officers,” and such information is incorporated herein by reference. There are no family relationships between Mr. Lutz and any director or executive officer of Savara, and Mr. Lutz has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. In connection with his appointment and effective as of the Effective Date, Mr. Lutz will receive an annual base salary of $510,000. Additionally, subject to Board approval, Mr. Lutz will receive a grant of (1) an option to purchase 70,000 shares of Savara’s common stock, which will vest in sixteen quarterly installments following the Effective Date, and (2) 35,000 restricted stock units, which will vest in full on the two-year anniversary of the Effective Date, in each case, subject to his continued service to Savara through the applicable vesting date.

     


    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On June 4, 2026, the stockholders of Savara approved an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock of Savara from 300,000,000 to 600,000,000 (the “Amendment”). We filed the Amendment on June 4, 2026 with the Secretary of State of the State of Delaware, and the Amendment became effective upon filing.

    The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 hereto and incorporated herein by reference.

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    At the Savara annual meeting of stockholders held on June 4, 2026 (the “Annual Meeting”), our stockholders elected each of the following individuals to serve on the Board of Directors until the next annual meeting of stockholders, or until his or her successor is duly elected and qualified.

     

    Nominees

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non Votes

    Matthew Pauls   156,349,041   2,798,767   61,270   24,628,938
    Nevan Elam   156,249,008   2,898,802   61,268   24,628,938
    Richard J. Hawkins   156,794,295   2,352,624   62,159   24,628,938
    Joseph S. McCracken   150,211,353   8,937,566   60,159   24,628,938
    David A. Ramsay   156,218,095   2,754,776   236,207   24,628,938
    An van Es-Johansson   158,694,187   460,731   54,160   24,628,938

    In addition, the following proposals were voted on at the Annual Meeting:

     

    1.

    Proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 to 600,000,000.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non Votes

    176,809,841   6,847,631   180,544   —

     

    2.

    Proposal to approve the amendment of the Savara Inc. 2024 Omnibus Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non Votes

    156,664,451   2,324,514   220,113   24,628,938

     

    3.

    Proposal to ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non Votes

    183,558,080   231,887   48,049   —

     

    4.

    Proposal to approve, on an advisory basis, the compensation of our named executives.

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non Votes

    156,706,529   2,307,296   195,253   24,628,938

     


    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.

      

    Description

    3.1    Savara Inc. Certificate of Amendment to Amended and Restated Certificate of Incorporation
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 8, 2026      

    SAVARA INC.

    a Delaware corporation

        By:  

    /s/ Dave Lowrance

         

    Dave Lowrance

    Chief Financial & Administrative Officer

    Get the next $SVRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    4/24/2026$9.00 → $11.00Outperform
    Oppenheimer
    10/20/2025$7.00Overweight
    Wells Fargo
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    More analyst ratings

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lowrance David L

    4 - Savara Inc (0001160308) (Issuer)

    3/20/26 4:16:03 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S exercised 1,807 shares at a strike of $1.76, increasing direct ownership by 0.60% to 302,644 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    2/17/26 5:30:13 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ramsay David A sold $121,220 worth of shares (20,000 units at $6.06), decreasing direct ownership by 0.78% to 2,533,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    12/19/25 5:00:19 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Savara Announces Chief Financial and Administrative Officer Transition

    -- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of this transition, the financial and administrative responsibilities of the role will be separated going forward. Robert Lutz, M.B.A., the Company's Chief Operating Officer, will assume the additional role of Chief Financial Officer, whi

    6/8/26 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

    Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage

    5/27/26 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

    Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: "Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)," presented by Y. Inoue, M.D.; sponsored by Savara Inc. Presented serum biomarker data from IMPALA-

    5/20/26 8:15:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Savara with a new price target

    Oppenheimer resumed coverage of Savara with a rating of Outperform and set a new price target of $11.00 from $9.00 previously

    4/24/26 8:30:27 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Savara with a new price target

    Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00

    10/20/25 8:03:17 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00

    8/15/25 9:10:16 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SVRA
    SEC Filings

    View All

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/2/25 7:59:29 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    4/1/25 7:00:04 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Savara Inc.

    8-K - Savara Inc (0001160308) (Filer)

    6/8/26 4:15:38 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Savara Inc.

    10-Q - Savara Inc (0001160308) (Filer)

    5/12/26 4:05:39 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Savara Inc.

    DEFA14A - Savara Inc (0001160308) (Filer)

    4/24/26 4:24:46 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

    Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

    9/24/24 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

     Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

    11/10/22 4:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara Announces Resignation of Chief Medical Officer

    Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

    8/26/22 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Financials

    Live finance-specific insights

    View All

    Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

    6/26/24 6:30:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

    6/25/24 8:05:00 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/12/24 10:25:33 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care